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1. Introduction
1.1. History of surgical revascularization
The concept of surgical revascularization for coronary artery disease (CAD) originated in the
early 20th century. A pioneer in this field is Beck, a surgeon who in 1935 developed an indirect
technique of myocardial revascularization by grafting a flap of the pectoralis muscle over the
exposed epicardium to create new blood supply. [1] Later, Beck also developed another
revascularization technique by anastomosis between the aorta and the coronary sinus. [2] In
1946, the Vineberg procedure was introduced in which the internal mammary artery (IMA)
was used to implant directly into the left ventricular and is hence considered the forerunner
of coronary artery bypass grafting (CABG). This technique was the first intervention docu‐
mented to increase myocardial perfusion and was successfully performed in over 5,000
patients between 1950 till 1970. [3-5] The major breakthrough in surgery, however, was the
invention of the heart-lung machine in 1953, which allowed surgeons to perform open-heart
procedures on a non-beating heart and controlled operating field while protecting other vital
organs. [6] Still it was not until 1960 when the first successful human coronary artery bypass
surgery was performed by Goetz and Rohman, who used the IMA as the donor vessel for
anastomosis to the right coronary artery. [7] The bypass graft technique as we know today was
developed by Favaloro in 1967. [8] In his physiologic approach in the surgical management of
coronary artery disease, Favaloro and his team initially used a saphenous vein autograft to
bypass a stenosis of the right coronary artery. Shortly hereafter, Favaloro began to use the
saphenous vein as a bypassing conduit. After the saphenous vein bypass procedure was
extended to include the left arterial system by Johnson [9], the use of the IMA for bypass
grafting was performed by Bailey and Hirose in 1968. [10] Arguably, the first successful IMA
– coronary artery anastomosis was already performed 4 years earlier by the Russian surgeon
Vasilii Kolesov. [11] Use of the radial artery (RA) as a bypass conduit was introduced by
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Carpentier in 1971 and fell into disrepute shortly after its introduction because of high failure
rates but was revisited as many of these original grafts appeared widely patent at 6 years. [12,
13] Initially used as a free graft in a fashion similar to that of the saphenous vein graft, more
recently the RA has been used as a T or Y graft from the left IMA (LIMA) or an extension graft
from the distal right IMA (RIMA). On the basis of superior long-term outcomes of arterial
conduits compared with vein grafts, other arteries have been used in CABG such as the
gastroepiploic artery (GEA), the inferior epigastric artery (IEA), the splenic artery, the
subscapular artery, the inferior mesenteric artery, the descending branch of the lateral femoral
circumflex artery, and the ulnar artery. However none of these arteries have shown similar
patency rates as the internal mammary artery.
Surgical revascularization in the current era - A number of studies and trials have consistently
shown the benefit of CABG in select patient populations. Indisputable, surgical revasculari‐
zation which in most cases is performed utilizing the saphenous vein for bypassing non LAD-
lesions and arterial bypass grafts for LAD lesions, has dramatically changed the management
of patients with ischemic heart disease. Currently, over 300,000 patients undergo CABG in the
United States each year. [14] Although the short-term outcomes of CABG are generally
excellent, patients remain at risk for future cardiac events due to progression of native coronary
disease and/or coronary bypass graft failure. [15-18] To illustrate, over half of saphenous vein
grafts (SVG) are occluded at 10 years post CABG and an additional 25% show significant
stenosis at angiographic follow-up. [19] Additionally, diseased grafts represent an increasing
proportion of culprit lesions and acute graft occlusion may cause acute coronary syndromes
(ACS). [20] In the next paragraphs we will describe in further detail the pathophysiologic
mechanisms that lead to coronary artery bypass graft failure, and elude to management
strategies.
2. Pathophysiology of coronary artery bypass graft failure
The use of the SVG, arterial grafts or both during CABG is largely depending on the site of
anatomic obstruction, the availability of good quality conduits, patient preferences, and the
clinical condition of the patient. Adequate arterial conduits are not always available, in contrast
SVG are usually of good quality and calibre and are easily harvested, and are thus commonly
used as conduits. However, there is an increasing interest for the use of arterial conduits as
coronary artery bypass grafts, especially for bypassing the left coronary artery. Although, the
choice to use arterial conduits partly depends on the coronary run-off, the long-term patency
of arterial grafts is superior for CABG compared to SVG. As more than half of SVG are occluded
at 10 years post CABG and an additional 25% show significant stenosis at angiographic follow-
up. [19] SVG failure is the main cause of repeat intervention either by redo CABG or PCI and
is even more common than the progression of native coronary artery disease in patients whom
underwent CABG. In spite the fact that SVG failure remains a significant clinical and economic
burden, the majority of CABG procedures continue to use SVG. [21]
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The concept of the ‘failing graft’ is one of a patent graft whose patency is threatened by a
hemodynamically significant lesion in the inflow or outflow tracts or within the body of the
graft. Salvage of the failing and failed bypass graft remains an important clinical and technical
challenge. The high incidence of graft failure has led to the evolution of graft surveillance
programs to detect ‘failing’ grafts and research has focussed on means to control the devel‐
opment of intimal hyperplasia. [22]
3. Histology of saphenous vein
The saphenous vein consists of three layers: the intima, media, and adventitia. The intima is
composed of a continuous layer of endothelial cells on the luminal surface of the vessel.
Beneath lies the fenestrated basement membrane embedded with a fragmented internal elastic
lamina. The media comprises of smooth muscle cells (SMC) arranged in an inner longitudinal
and an outer circumferential pattern with loose connective tissue and elastic fibers interlaced.
The middle muscle layer is most extensive at the insertion points of the valves and leaflets.
The adventitia forms the outer layer and consists of longitudinally arranged SMC, collagen
fibers and a network of elastin fibers, in addition to vascular and nerve supplies to the
vessel.The great saphenous vein is the most frequently used conduit for myocardial revascu‐
larization but other venous conduits such the short saphenous vein or upper extremity veins
(cephalic and basilica) can be used as well.
4. Saphenous vein graft failure
Studies of saphenous veins harvested for bypass procedures have shown that many have
abnormal histological and physical attributes. [23,24] Moreover, the quality of the saphenous
vein can have significant clinical consequences. Therefore, vein grafts in the arterial circulation
must be considered as a viable, constantly adapting and evolving conduit.
Several  intrinsic and extrinsic factors may play a role in the mechanism of SVG failure.
At the time of harvest, the quality of the saphenous veins may be poor, demonstrating a
spectrum  of  pre-existing  pathological  conditions  ranging  from  significantly  thickened
walls to post phlebitic changes and varicosities. Between 2% and 5% of saphenous veins
are unusable and up to 12% can be considered diseased which reduce the patency rate
by  one  half  compared  to  non-diseased  veins.  [25]  In  addition,  the  inevitable  vascular
trauma that occurs during SVG harvesting itself can also lead to damage to the endothe‐
lium and SMC and thereby contribute  to  graft  failure.  Surgical  manipulation and high-
pressure  distension  to  reverse  spasm  during  harvesting  leads  to  loss  of  endothelial
integrity  and  the  antithrombogenic  attributes  of  the  endothelium,  rendering  the  SVG
prone to subsequent occlusive intimal hyperplasia and/or thrombus formation. [26] Dur‐
ing harvesting the vasa vasorum and nervous network of the SVG are devided, making
the  graft  dependent  on  diffusion  for  weeks  until  adequate  circulation  is  esthablished.
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[27-32]  Ischemic  insult  and  decreased  production  of  nitric  oxide  and  adenosine  may
cause SMC proliferation. [33] As it has been demonstrated that intimal hyperplasia does
not occur in vein-to-vein isografts,  it  can be stated that pathologic changes seen in SVG
in the arterial circulation are predominantly caused by hemodynamic and physiochemical
changes. [34]
SVG failure can be divided into three temporal categories: early (0 to 30 days), midterm
(30 days to 1 year) or late (after 1 year).  Early SVG failure due to thrombotic complica‐
tions  is  mainly  attributable  to  technical  errors  during  harvesting,  anastomosis  or  com‐
prised anatomic runoff.  [19,35-37]  It  occurs  in  15% to 18% of  VG during the 1st  month.
[38-40] Early thrombotic complications in SVG in the arterial circulation are caused by a
reduction  of  tissue  plasminogen  activator,  attenuation  of  thrombomudulin  and reduced
expression of heparin sulphate. [41]
Midterm SVG failure is mainly caused by fibrointimal hyperplasia as it serves as the founda‐
tion for subsequent graft atheroma leading to occlusive stenosis. The release of a variety of
mediators, growth factors, and cytokines by the injured endothelium, platelets and activated
macrophages will cause migration and proliferation of SMC. Diminished production of
endothelial nitric oxide (NO), prostaglandin 12 and adenosine will further contribute to and
enhanced SMC proliferation, leading to development of neointimal hyperplasia.
[19,33,37,42-44] Changes in the flow pattern within the vessel (shear stress) an ischemic insults
may contribute to changes in the SVG at this stage. SVG are exposed to much higher mechanical
pressure that they were adapted to (arterial versus venous blood pressure) which can poten‐
tially stimulate SMC proliferation. Moreover, after encountering arterial flow patterns
increased levels of intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and
monocyte chemotactic protein-1 will facilitate leukocyte-endothelial interactions so that
leukocyte infiltration of the lesions will ensue. [34] Finally, the adaptive response to hemody‐
namic factors, i.e. wall shear stress, may affect the distal site of the anastomosis leading to SVG
failure. [45,46] Midterm SVG failure accounts for an additional 15% to 30%. [47,48] In the course
of vessel remodelling, late SVG failure is characterized by progression of intimal fibrosis at the
cost of a reduction in cellularity which may contribute to progression of SMC apoptosis.
[19,34,41,44] In addition, perivascular fibroblasts may also be involved in neointimal formation
and matrix deposition as these cells may exhibit contractile elements while migrating from the
adventitia towards the media. [49] After 1 year most SVG stenosis is due to atherosclerosis but
although vein graft atherosclerosis is accelerated compared to arteries, evidence show that a
fully evolved plaque appear after 3 to 5 years of implantation. [35,47,50] In SVG there is no
focal compensatory enlargement in the stenotic segments which is in contrast to native
atherosclerotic arteries in which the development of an atherosclerotic plaque is associated
with enlargement of the vessel and preservation of the lumen area until plaque progression
exceeds the compensatory mechanism of the vessel. [51] Several studies show that SVG
patency at 10 years is no more than 50% to 60%. [19,41,52,53] Finally, several studies have
suggested a role of immune cells in neointimal formation as macrophages are found in the
intima, while T-lymphocytes are present in the adventitia of neointimal lesions wit a predom‐
inance of CD4+ cells. [54-56]
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In  a  later  stage  atherosclerotic  lesions  may  be  complicated  by  aneurysmal  dilatation
which  is  found to  correlate  with  thrombosed SVG.  (66)  The  occurrence  of  atheroembo‐
lism form the diseased graft  or  plaque rupture may cause late  thrombosis  necessitating
revascularization therapy. [57,58] In general,  SVG thrombosis is the major cause of mor‐
bidity and mortality. [19,41]
Predictors of graft patency 3 years after CABG were evaluated by Veterans Affairs Cooperative
Study Group. [59] Multivariable analysis showed that the only factors that were predictive
were vein preservation solution temperature ≤5ºC, serum cholesterol, the number of proximal
anastomoses ≤2, and recipient artery diameter >5 mm. Thus, predictors of 3-year graft patency
are most closely related to operative techniques and the underlying disease. In another study,
factors that predict the late progression of SVG atherosclerosis were evaluated in 1248 patients
in the Post-CABG trial. [47] Factors independently associated with the progression of disease
were maximum stenosis of the graft at baseline angiography, years after CABG, moderate
therapy to lower LDL cholesterol, prior MI, high triglyceride levels, small minimum graft
diameter, low HDL concentration, high LDL concentration, high mean arterial pressure, low
left ventricular ejection fraction, male gender, and current cigarette smoking. Finally, concerns
have been raised about the possibility of worse outcomes when a SVG is used for multiple
distal anastomosis compared to single anastomosis. In a substudy of the PREVENT IV trial,
the use of SVG conduits with multiple distal anastomoses was associated with a significantly
higher rate of ≥75 percent stenosis of the SVG on angiography at one year. [60] Moreover,
clinical follow-up showed a trend towards a higher rate of the adjusted composite of death,
MI, or revascularization at five years.
Noteworthy, the clinical impact of SVG failure is still debated. Not all grafts that have
angiographic stenosis or occlusion will cause symptoms, and probably a substantial of SVG
that fail do not impact outcomes.
5. Histology of arterial grafts
Several arterial conduits are suitable for myocardial revascularization and the arterial conduits
can be divided into 3 types according to functional class (Table 1). Type I arterial grafts are the
somatic arteries including the IMA, IEA, and subscapular artery. Type II arterial grafts are the
splanchnic arteries including the GEA, splenic artery, and inferior mesenteric artery. Type III
arterial grafts are the limb arteries including the RA, ulnar artery, and lateral femoral circum‐
flex artery. Compared to functional class type II and III, type I is less spastic. [61] Although the
full length of arterial grafts is reactive, the major muscular components are located at the two
ends of the artery (muscular regulator). [62] Therefore, in terms of preventing vasospasm of
arterial grafts, trimming off the small and highly reactive distal end of the grafts (IMA, GEA,
IEA, or other grafts) may be important and clinically feasible.
Studies have demonstrated that there are differences between arterial and venous grafts: 1)
arterial grafts are less susceptible to vasoactive substances then veins [63]; 2) the arterial wall
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is supplied by the vaso vasorum and in addition through the lumen, whereas the veins are
only supplied by the vaso vasorum [64]; 3) the endothelium of the arteries may secrete more
endothelium-derived relaxing factor [65]; 4) the structure of the artery is subject to high
pressure, whereas the vein is subjected to low pressure. While the SVG have to adapt to the
high pressure, the arterial grafts do not which may partly explain the difference in the long-
term outcome.
Similar like SVG, the arterial grafts can also be divided into three layers: the intima, media,
and adventitia. As a result of location at different parts of the body and supply to different
organs, differences in gross anatomy among arterial grafts have been observed. Divergent
anatomic structures of the arteries have been observed. One of the most obvious differences
is that arteries such as the GEA, IEA, and RA contain more smooth muscle cells in their walls
and are therefore less elastic compared to other arteries such as the IMA which may be more
elastic because they contain more elastic laminae. [64] Such structure divergence may also
explain the difference in phsysiologic and pharmacologic reactivity.
6. Arterial graft failure
The need for repeat revascularization is substantially reduced with the use of arterial conduits,
since long-term patency is much higher compared to SVG. [66-68] In contrast to SVG, arterial
grafts appear to be more resistant to the influence of atherogenic factors and incur only minor
traumatic and ischemic lesions, since they are not removed from the blood circulation but are
prepared locally, with few ligations and preservation of blood flow. [69] Since 1986, the LIMA
has been used in more than 90% of CABG procedures. Less frequently, the RIMA is used. The
early patency of a LIMA anastomosed to the left anterior descending (LAD) is reported to be
almost 99%. [70] The mean patency of LIMA to coronary conduit at 5 years is reported 98%,
at 10 years it is 95%, and at 15 years it is 88%. [71] Differences are observed between territory
Type I - Somatic arteries Less spastic Internal mammary artery
Inferior epigastric artery
Subscapular artery
Type II - Splanchnic arteries Spastic Gastroepiploic artery
Splenic artery
Inferior mesenteric artery
Type III - Limb arteries Spastic Radial artery
Ulnar artery
Lateral femoral circumflex artery
Table 1. Functional classification of arterial grafts according to physiological and pharmacological contractility,
anatomical, and embryological characteristic
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grafted, the 10 year LIMA patency to the LAD is reported to be 96% and to the circumflex (Cx)
89%. [72] The early patency of the RIMA anastomosed to major branches of the left circumflex
artery is approximately 94%. [70] The mean RIMA patency at 5 years is reported to be 96%, at
10 years it is 81% and at 15 years it is 65%. [71] Again differences are observed, the RIMA graft
patency to the LAD artery is 95% at 10 years and 90% at 15 years. Ten-year RIMA patency to
the Cx marginal is 91%, right coronary artery is 84%, and posterior descending artery is 86%.
[72] In situ RITA and free RITA had similar ten-year patency, 89% vs 91% respectively. RA
patency is reported to range between 83% to 98% at 1 to 20 years but lower rates have been
reported. [73] The patency rate estimated by the Kaplan-Meier method for the GEA conduit
was 96.6% at 1 month, 91.4% at 1 year, 80.5% at 5 years, and 62.5% at 10 years. [74] Arterial
grafts are not uniform in their biological characteristics and difference in the perioperative
behaviour and in the long-term patency may be related to different characteristics. It should
be taken into account in the use of arterial grafts that some grafts need more active pharma‐
cological intervention during and after operation to obtain satisfactory results.
Although, the IMA is the most used conduit to restore the blood flow to the LAD, it is less easy
to use because of its complicated preparation and postoperative complications. Specific
reasons for not to use the RIMA may include additional time to harvest, concerns over deep
sternal wound infection, myocardial hypoperfusion, and unfamiliarity. Besides the potentially
deleterious effect on the vascular supply of the forearm and hand, potential spasm and size
matching to target coronary artery are the main drawback for the use of RA in CABG. [75,76]
Although all arterial grafts may develop vasospasm, it develops more frequently in the GEA
and RA, than the IMA and IEA. [13,77] Two types of vasoconstrictors are found to be important
spasmogens in arterial grafts. [78] Type I vasoconstrictors are the most potent and they strongly
contracts arterial grafts even when the endothelium is intact. The constrictors are endothelin,
prostanoids such as thromboxane A2 and prostaglandin F2α, and alpha1-adrenoceptor agonists.
Type II vasoconstrictors induce only weak vasoconstriction when the endothelium is intact,
but play an important role in the spasm of arterial grafts when the endothelium is destroyed
by surgical manipulation. Type II vasoconstrictor is 5-hydroxytryptamine.
Early IMA graft failure is attributed to technical errors and distal anastomosis. [79,80] Non‐
technical factors that may affect the patency of the arterial graft are high levels of LDL
cholesterol and triglycerides, and high levels of lipoprotein(a), a thrombogenic molecule that
is related to the hypercoagulable state. Other classical risk factors for coronary artery disease,
such as diabetes mellitus, smoking and hypertension may also affect the patency of the arterial
graft. Age may be of influence the quality of the arterial graft.
Furthermore, competitive flow and low-flow profoundly affect graft patency. Low-grade graft
stenoses in the target artery proximally are a major cause of competitive flow which may lead
to a decrease in antegrade flow in the arterial graft causing early failure (‘disuse athrophy’).
The SVG and IMA are more tolerant than the RA and GEA conduits. This is likely to be related
to biological differences as the RA and GEA have a thick layer of smooth muscle or poor
endothelial function in these muscular conduits. Therefore, it is recommended to avoid
grafting target arteries with a stenosis less than 90% with RA grafts. [81]
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Atherosclerosis in arterial grafts can develop before coronary grafting when the graft is in the
in situ native position, or after. The incidence of atherosclerosis in native arteries in the in situ
position in the four major arterial grafts is low, especially in the IMA. [64] The incidence of
atherosclerosis in bypass grafts is also low, in IMA grafts even as late 15 to 21 years after CABG.
[67,82] However, the degree of stenosis in the native vessel is a major predictor of IMA graft
patency. The observed association between non-significant stenosis of the native artery and
high occlusion rate of the arterial bypass conduit raises concerns about the use of IMA in the
treatment of native vessels with only mild or moderate stenosis. [83] In addition, the target
vessel for the IEA must be one that is completely occluded or severely stenotic, with low
coronary resistance, and in territories not totally infarcted to avoid “string sign” (conduit <1
mm diameter). Although the incidence of atherosclerosis is low in arterial grafts, 2 other
morphologic changes may be present in arterial graft, fibrointimal proliferation and fibrosis
representing organized thrombus. [84] The presence of fibrointimal proliferation is associated
with long-term IMA graft narrowing and may be an important factor for late graft failure.
Despite hypertension was associated with increased fibrointimal proliferation in SVG, this
correlation could not be found in IMA grafts. [84]
7. Treatment of coronary artery bypass graft failure
Following graft revascularization, patients remain at very high risk for subsequent clinical
events. In a large study from the Duke Cardiovascular Databank, patients who underwent
catheterization 1 to 18 months after their first CABG were evaluated. [85] Patients were
classified on the basis of their worst SVG stenosis as having no (<25%), noncritical (25% to
74%), critical (75% to 99%), or occlusive (100%) SVG disease and the primary outcome measure
was the composite of death, MI or repeat revascularization. At 10-years, the corresponding
adjusted composite event rates were 41.2%, 56.2%, 81.2%, and 67.1%, respectively (p<0.0001)
and most events occurred immediately after catheterization in patients with critical and
occlusive SVG disease. Multivariate analysis revealed critical, non-occlusive SVG disease as
the strongest predictor of composite outcome (hazard ratio 2.36, 95% CI [2.00-2.79], p<0.0001).
Many patients with recurrent stable angina following CABG can be treated medically for their
symptoms and risk factor reduction. Evaluation for ischemia is as in other patients with stable
angina without prior CABG. However, early diagnostic angiography is suggested as the
different anatomic possibilities, i.e. graft stenosis or progression of native vessel disease in
nonbypassed vessels can lead to recurrent ischemia. In patients with recurrent angina, ACS,
change in exercise tolerance, positive exercise test after CABG, an increased risk for coronary
events is observed. [86-88]
8. Medical therapy
In all patients with coronary heart disease aggressive risk factor reduction is recommended
which includes aspirin, treatment for hypertension and serum lipids, avoidance of smoking,
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and controlling serum glucose in diabetic patients. The bypass angioplasty revascularization
investigation (BARI) trial illustrated that intensive risk-factor modification and hypolipid
medication use slows atherosclerosis progression within native coronary arteries of CABG-
treated patients and may to a lesser extent improve long-term patency of surgical conduits. [89]
Antiplatelet therapy - Antiplatelet therapy is recommended following CABG since it improves
SVG patency and clinical outcomes. The 2008 EACTS guideline on antiplatelet and anticoa‐
gulation management in cardiac surgery [90] recommends that aspirin should be given
postoperatively to all patients without contra-indications after CABG in order to improve the
long-term patency of SVG. The recommended dose given is 150—325 mg. Several studies have
shown a trend towards maximal benefit with 325 mg/day in the first year. [91-95] In contrast,
there is no evidence that the use of aspirin after coronary artery bypass grafting improved the
patency of arterial grafts. However, aspirin may be recommended on the basis of improved
survival of patients in general who have atherosclerotic disease.
The optimal timing of the first dose of aspirin for patients after CABG was investigated in a
meta-analysis of 12 studies and found that the benefit of aspirin was optimal if started at 6 h
after surgery. [96] Although, the largest risk reduction was observed when aspirin was given
at 1 h after operation, there was a non-significant increase in the rate of re-operation in this
group. [91] In contrast, there was no benefit found in giving aspirin if starting more than 48 h
postoperatively. [97] Practically, Aspirin should be commenced within 24 h of CABG.
Whether clopidogrel given in addition of aspirin to high-risk patients after CABG would
reduce thrombotic complications was evaluated in several studies. Registry data showed
that adding clopidogrel to aspirin was independently associated with a decrease in recur‐
rence  of  anginal  complaints  and  adverse  cardiac  events  following  off-pump  CABG.
Nonetheless, clopidogrel use beyond 30 days did not show a significant effect on adverse
cardiac  events.  [98]  In  the  randomized CASCADE (Clopidogrel  After  Surgery for  Coro‐
nary Artery Disease) study, aspirin monotherapy was compared with aspirin plus clopi‐
dogrel  in  113 patients  undergoing CABG and SVG intimal  hyperplasia  was determined
by  intravascular  ultrasound  at  1  year.  [99]  Compared  with  aspirin  monotherapy,  the
combination of  aspirin plus clopidogrel  did not significantly reduce SVG intimal hyper‐
plasia  1  year  after  CABG.  Although  the  study  was  not  powered  for  clinical  outcomes,
there was no significant difference in SVG patency or cardiovascular events, neither was
there a difference in the incidence of major bleeding between the 2 treatment groups at 1
year.  Moreover,  the  superiority  of  clopidogrel  over  aspirin  for  optimising graft  patency
after CABG has not been established and thus aspirin should be regarded as the drug of
first choice, however, clopidogrel is an acceptable alternative to aspirin. [90]
In patients whom underwent CABG for ACS subgroup analyses of the CAPRIE (Clopidogrel
versus Aspirin in Patients at Risk of Ischemic Events) and CURE (Clopidogrel in Unstable
angina to prevent Recurrent Events) study provides supportive evidence to prescribe clopi‐
dogrel for 9 to 12 months in addition to aspirin. [100,101] In patients undergoing coronary
bypass surgery with a coronary stent in situ implanted within 1 year, clopidogrel should be
continued if the stented vessel has not been grafted. Finally, in patients with SVG failure treated
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with PCI, prehospital use of antiplatelet therapy compared with patients not using antiplatelets
was associated with lower occurrence of major adverse cardiac events after SVG intervention.
[102] Also, DAPT did not improved outcomes when compared to single antiplatelet therapy.
Warfarin – Conflicting evidence is reported whether warfarin in addition to aspirin is beneficial
in patients post CABG. In an extended follow-up of 7.5 years of the post CABG trial, low-dose
anticoagulation compared with placebo reduced the rate of death by 35%, deaths or myocardial
infarction (MI) by 31%, and the composite clinical endpoint of death, MI, stroke, CABG, or
angioplasty by 17%. [103] However, in a smaller randomized trial, moderate-intensity oral
anticoagulation alone or combined with low-dose aspirin was not superior to low-dose aspirin
in the prevention of recurrent ischemic events in patients with non-ST-elevation ACS and
previous CABG. [104] Currently, the American College of Chest Physicians (ACCP) Evidence-
Based Clinical Practice Guidelines recommended that oral anticoagulation in addition to
aspirin can be considered only when it is indicated for other reasons. [105]
Lipid lowering therapy – Clinical trials have shown that lipid lowering therapy (in particular
statins) is beneficial in patients who have undergone CABG. [103,106-110] Besides the lipid
lowering effect, statins also exert a number of pleiotropic effects on the vascular wall which
may effect SVG in a similar way. In SVG, statins have shown to reduce vascular oxidative
stress, improve NO bioavailability and reduce vascular inflammation, all critical components
of SVG failure. [111] Subsequently, statins have systemic antithrombotic and anti-inflamma‐
tory effects and their administration may prevent acute SVG failure post CABG. [112] Ag‐
gressive lipid lowering therapy may be beneficial for long-term patency of grafts. In the
randomized Post CABG trial, patients who had undergone bypass surgery 1 to 11 years before
base line with elevated serum LDL-cholesterol concentrations (130 to 175 mg/dL / 3.4 to 4.5
mmol/L) were assigned to receive either aggressive lipid lowering therapy with lovastatin and,
if needed, cholestyramine (target LDL-cholesterol <100 mg/dL / 2.6 mmol/L) or to moderate
therapy (target LDL-cholesterol of approximately 134 mg/dL / 3.5 mmol/L). [106] Compared
to a moderate strategy, aggressive lipid lowering therapy was associated with a delay in the
progression of graft disease at an average of 4.3 years as assessed by angiography. Moreover,
after clinical follow-up of 7.5 years, a 30% reduction in revascularization procedures and a 24%
reduction in the composite endpoint of cardiovascular death, MI, stroke, CABG, or angioplasty
were seen. [103] Similar findings were observed in a post hoc analysis from the TNT trial. In
patients with previous CABG, simvastatine 80 mg compared to simvastatine 10 mg, was
significantly more effective in reducing the rate of a combined cardiovascular endpoint at a
median follow-up of 4.9 years (9.7% versus 13.0%). [110] Repeat revascularization with either
CABG or PCI was also significantly reduced in patients assigned to the higher dose (11.3%
versus 15.9%).
Antiplatelet agents and statin therapy are the only modalities with proven efficacy for the
prevention of SVG stenosis. The routine use of beta blockers, calcium channel blockers,
angiotensin converting enzyme (ACE) inhibitors, or nitrates post CABG is not supported by
data, however, many of these patients require beta blockers and ACE inhibitors for preexistent
heart failure or MI according to the ACC/AHA guideline recommendations. [113,114]
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The PREVENT IV trial, including almost 3,000 patients that underwent CABG, demonstrated
that rates of use of secondary prevention medications in patients with ideal indications for
these therapies are high for antiplatelet agents and lipid-lowering therapy, but suboptimal for
beta-blockers and ACE inhibitors or ARBs. [115] The study demonstrated that the use of
multiple secondary prevention medications after CABG was associated with significant
improve in clinical outcome death or MI at 2 years (4.2% in patients taking all indicated
medications versus 9.0% in patients taking half or fewer of the indicated medications). No
association was found between the use of most individual medications and subsequent
outcomes, thus underscoring the importance of ensuring appropriate secondary prevention
measures after CABG.
9. Guidelines on revascularization in patients with prior CABG
In the European Society of Cardiology (ESC)/ European Association for Cardio-Thoracic
Surgery (EACTS) guidelines on myocardial revascularization [116] published in 2010 states
that in acute post-operative graft failure PCI may be an alternative to re-operation with
acceptable results and fewer complications. [117] The target for PCI is the body of the coronary
artery of the arterial graft while freshly occluded SVG or the anastomosis itself should be
targeted due to the risk of embolization or perforation. When multiple grafts are occluded or
the graft or native coronary artery appears unsuitable for PCI, surgery should be favoured. In
asymptomatic patients, redo CABG or PCI should only be considered if the graft or coronary
artery is of good size, severely narrowed and supplies a large territory of myocardium. Redo
CABG or PCI should be decided by the Heart Team.
Repeat revascularization in patients with late graft failure is indicated in the presence of severe
anginal symptoms despite anti-anginal medication. In patients with mild or no symptoms
repeat revascularization is dependent on risk stratification by non-invasive testing. [118,119]
In patients with previous CABG, PCI has worse acute and long-term outcomes than in patients
without prior CABG. Redo CABG has a two- to four-fold higher mortality than the first
procedure which is mainly driven by comorbidity and less by the re-operation itself. [120,121]
There is limited data comparing the efficacy of PCI with redo CABG in patients with previous
CABG. In a propensity analysis of long-term survival after redo CABG or PCI in patients with
multivessel disease and high-risk features, short-term outcome was very favourable, with
nearly identical survival at 1 and 5 years. [118] However, in the AWESOME RCT and registry
the overall in-hospital mortality was higher in the redo CABG group compared to the PCI
group. [17,122] Because of the initial higher mortality of redo CABG and comparable long-
term mortality, the guidelines state that PCI is the preferred revascularization strategy in
patients with LIMA or amenable anatomy. Redo CABG is preferred in patients with more
diseased or occluded grafts, reduced systolic function, total occlusions of native coronary
arteries or in the absence of a patent arterial graft. [118] If possible, the IMA is the conduit of
choice when performing redo CABG. [123]
In the 2012 appropriateness criteria for coronary revascularization focussed update of the
American College of Cardiology Foundation Appropriateness Criteria Task Force (ACCF),
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Society for Cardiovascular Angiography and Interventions (SCAI), Society of Thoracic
Surgeons (STS), American Association for Thoracic Surgery (AATS), American Heart Associ‐
ation (AHA), and the American Society of Nuclear Cardiology (ASNC) it is stated that in
patients with prior CABG, the presence of high-risk findings on noninvasive testing, higher
severity of symptoms, or an increasing burden of disease in either the bypass grafts or native
coronaries tended to increase the likelihood of an appropriate rating. [119] In patients with
prior CABG receiving no or minimal anti-ischemic therapy or having low-risk findings on non-
invasive testing revascularization was considered inappropriate. No specific recommenda‐
tions are provided on the strategy for revascularization, performing redo CABG or PCI.
Both the ESC/EACTS guidelines on myocardial revascularization and the ACCF/SCAI/STS/
AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization
focused update do not provide recommendations for patients with prior CABG presenting
with (non) ST segment elevation myocardial infarction (STEMI) or ACS.
10. Percutaneous coronary intervention
Implantation of coronary stents has become the preferred revascularization strategy for
treatment of graft lesions, because redo CABG is associated with an increased morbidity and
mortality. [17,124-129] Compared to native vessel stenting, stenting of graft lesions is associ‐
ated with higher rates of periprocedural events as well as cardiac events at follow-up, due to
distal embolization and subsequent no-reflow and higher percentages of restenosis. [124,125,
130,131] This increased risk is mainly attributed to the friable, degenerated atheromatous and
thrombotic debris that develop when SVGs deteriorate. [132] Moreover, patients with graft
intervention often have a higher generalized atherosclerotic burden and more comorbidities.
[130,131] To date, SVG graft intervention accounts approximately for 5% to 10% of all PCI.
Early graft failure - The incidence of early graft failure within 24 h after CABG is about 1% to
3%. [133] Perioperative graft failure following CABG may result in acute myocardial ischemia
which may necessitate acute secondary revascularization procedure to salvage myocardium,
preserve left ventricular function and improve patient outcome. Perioperative MI and rise in
cardiac markers after CABG is associated with a substantially increased in-hospital morbidity
and mortality. [134-136] The most common graft-related causes of myocardial ischemia after
CABG are graft occlusion due to acute graft thrombosis, graft kinking or overstretching,
postoperative graft spasm and subtotal or hemodynamic relevant anastomotic stenosis.
[137,138] Nongraft-related causes for myocardial ischemia after CABG are surgery-related
possibly due to surgical manipulation on pre-existing microembolizing and disintegrating
unstable plaque and include inadequate cardioplegic perfusion and myocardial protection,
incomplete revascularization, or distal coronary microembolization. [139-141] Rapid identifi‐
cation of early graft failure after CABG and diagnostic discrimination from other causes
enables an adequate reintervention strategy for re-revascularization, i.e. redo CABG or PCI,
and may prevent irreversible myocardial ischemia. Thus far, limited non-randomized data is
available showing that in patients with acute perioperative myocardial ischemia due to early
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graft failure following CABG, emergency PCI may limit the extent of myocardial cellular
damage compared with redo CABG. [133] A nonsignifiant numerical difference was observed
in in-hospital and 1-year mortality between the PCI group or redo CABG (12.0% and 20.0% in
PCI group versus 20.0% and 27% in redo CABG group). Moreover, compared to acute redo-
CABG, emergency PCI is quicker and less invasive. Importantly, in this study patent grafts
were observed in 25% to 34% of the patients, therefore repeat coronary angiography should
be applied when myocardial ischemia due to acute graft failure is suspected. Regarding the
type of bypass graft, LIMA graft failure may be responsible for acute ischemic complications
after CABG in at least a third up to half of the cases. [133,138,142]
Recurrent angina during the early postoperative period is usually due to a technical problem
with a graft or with early graft closure and there is an indication for prompt coronary angiog‐
raphy with percutaneous revascularization. The feasibility of PCI in patients presenting with
clinical evidence of ischemia within 90 days of CABG was evaluated in 2 registries. Most
patients presented with ACS and the most common cause of graft failure was occlusion or
thrombosis. Both registries showed that patients with graft failure can undergo PCI with a
relatively low risk for in-hospital mortality or nonfatal major complications. [143,144]
SVG failure - Recurrent angina after the first few months after CABG is caused by both graft
disease and by progression of atherosclerosis in non-bypassed vessels. Percutaneous inter‐
vention in SVG lesions was evaluated in several randomized studies. The SAVED (Saphenous
Vein de Novo) study randomized 200 patients with SVG lesions to placement of Palmaz-Schatz
bare metal stent (BMS) or standard balloon angioplasty (BA) and demonstrated that compared
to BA, bare metal stents (BMS) were associated with a higher procedural success (92% vs. 69%,
p<0.001) but they had more frequent hemorrhagic complications (17% vs. 5 %, p<0.01). [145]
At 6 months, a non-significant reduction in angiographic restenosis was observed (36% vs.
47%, p=0.11) and clinical follow-up at 9 months showed that freedom from death, MI, repeated
bypass surgery, or revascularization of the target lesion was significantly better in the stent
group (73% vs. 58 %, P = 0.03). Based on the results of the SAVED study, the majority of patients
with SVG stenosis are treated with stenting. To prevent distal embolization form friable
atheroemboli, and in addition may serve as a smooth-muscle cell barrier to decrease restenosis,
stents covered with a mesh, most commonly polytetrafluorethylene (PTFE), were evaluated.
However, 3 prospective randomized trails have not shown benefit with covered stents with
respect to major adverse cardiac events nor in preventing restenosis. [146-148]
In native coronary arteries, drug-eluting stents (DES) have demonstrated a marked reduction
in in-stent restenosis compared to BMS in the treatment of coronary artery disease. Several
DES with different stent platforms, polymers or drugs are available. In the RRISC (Reduction
of Restenosis in Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent) trial, 75 patients
were randomized to sirolimus-eluting stent (SES) or BMS. [149] At 6 months follow-up, in-
stent late loss was significantly reduced in SES (0.38 ± 0.51 mm vs. 0.79 ± 0.66 mm in BMS).
Target lesion revascularization rate was also significantly reduced (5.3% vs. 21.6%) but no
difference in death and MI was observed. Howbeit, a post hoc analysis of RRISC trial at 3 years
reported similar rates of target vessel revascularization and while statistically underpowered
for clinical outcomes, significantly higher all-cause mortality was reported with SES compared
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with BMS. [150] The SOS (Stenting of Saphenous Vein Grafts) trial randomized 80 patients to
either paclitaxel-eluting stent (PES) or BMS and showed significant reduction in primary end
point, binary angiographic restenosis at 12 months (9% vs. 51%). [151] At 1.5 years clinical
follow-up the PES patients had a significant reduction in target lesion revascularization (5%
vs. 28%), target vessel failure (22% vs. 46%) and a trend towards less MI (15% vs. 31%) but
increased mortality (12% vs. 5%). In contrast to the long-term results of the RRISC study, at a
median follow-up of 35 months PES treated-patients had a significantly lower incidence of MI
(17% vs. 46%), target lesion revascularization (10% vs. 41%), and target vessel failure (34% vs.
72%) as well as a trend toward less definite or probable stent thrombosis (2% vs. 15%). All-
cause mortality (24% vs. 13%) and cardiac mortality (7% vs. 13%) did not differ between
groups. [152] More evidence was provided in the ISAR-CABG (Prospective, Randomized Trial
of Drug-Eluting Stents Versus Bare Metal Stents for the Reduction of Restenosis in Bypass
Grafts). In this study, 610 patients with diseased SVGs were randomized to DES and BMS and
the combined incidence of death, MI, and target lesion revascularisation at 1 year was
significantly lower in the DES group than in the BMS group (15.4% vs. 22.1%) which was
mainly driven by a nearly 50% relative reduction in the risk of target lesion revascularization
(7.2% vs. 13.1%), with non-significant differences in mortality. [153] Consistent results of
improved efficacy with DES and no significant safety hazard were reported in different meta-
analyses which also included non randomized trails. [154-157] The RRISC, SOS and ISAR
CABG all compared first-generation DES to BMS. The SOS-Xience V (Stenting of Saphenous
Grafts-Xience V) prospectively examined the frequency of angiographic in-stent restenosis in
SVG lesions 12 months after implantation of everolimus-eluting stent (EES), a second gener‐
ation DES. Use of EES in SVGs is associated with high rates of stent strut coverage and high
malapposition rates at 12 months post implantation as assessed by optical coherence tomog‐
raphy, however, clinical results are to be waited. [158] Finally, in a multicenter analysis no
difference was observed in real-world patients comparing first-generation DES to BMS. [159]
In a meta-analysis including 29 studies (3 randomized controlled trials (RCT)) involving over
7500 patients, the authors stated that DES may decrease TVR rate in treatment of SVG stenoses
but no differences in reinfarction rate, stent thrombosis or mortality was found between the
DES and BMS groups in the RCT’s. [160] In contrast, the observational data showed lower risk
for MI, stent thrombosis and death in the DES group. This may be a result of patient selection
bias in the observational studies or represent a true finding that was not detected in the RCT
analysis due to limited statistical power.
Stents are effective as treatment for focal lesions, however, the optimal treatment strategy for
a diffusely degenerated SVG is uncertain. Endoluminal reconstruction with stent omplantation
has been suggested as a treatment for diffuse lesions. This was evaluated in a study including
126 patients with diffusely degenerated stenosed or occluded SVG treated with stents. [161]
At 3 year follow-up, survival free of death, infarction, or revascularization was only 43%.
Regarding stenting technique in SVG lesions, it has been suggested that direct stenting,
compared to predilatation with balloon angioplasty, may be beneficial as trapping of debris
could decrease distal embolization that may occur from repeated balloon inflations. Registry
data showed that in unselected patients who underwent SVG intervention direct stenting was
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associated with a lower CK-MB release and fewer non-Q-wave MI. [162] These results needs
to be confirmed in a prospective randomized trial.
After PCI of SVG, progression of disease outside the stented segment can lead to high rates of
restenosis. Therefore, treatment of native coronary artery lesions is preferred to treatment of
degenerated SVG if feasible. In addition, in patients with prior CABG, early diagnostic
angiography can be important as there is a high success rate of percutaneous coronary
intervention (PCI) at the time of subtotal occlusion; and the substantial consequences of the
loss of a bypass graft through total occlusion (e.g, low success and high complication rates of
PCI for totally occluded SVG, and difficult to control angina).
A numerous of predictors for worse outcome after percutaneous SVG intervention have been
identified. Multivariate analysis revealed that major CK-MB release after SVG intervention
and renal insufficiency are powerful independent predictor of all-cause mortality. [163-165]
Lesion length, greater angiographic degeneration of SVG, and larger estimated plaque volume
which may result in a greater likelihood of distal embolization and myocardial necrosis after
intervention, have been identified as predictors of 30-day major adverse cardiac events after
SVG intervention. [166,167] Sexe also appeared to be a predictor as women have a significantly
higher 30-day cumulative mortality rate compared with men (4.4% vs. 1.9%), a higher
incidence of vascular complications (12% vs. 7.3%), and postprocedural acute renal failure
(8.1% vs. 4%). [168] Whether specific stent platforms, polymers or drugs are more appropriate
in SVG and arterial graft lesions has not been addressed at this time.
Arterial graft failure - Due to the superior long-term patency of arterial grafts, in specific the
IMA, they are the vascular conduit of choice for patients undergoing CABG and the increasing
frequency of their use has resulted in a small but increasing need for revascularization. In
arterial graft failure, ostial stenoses are the least common and the pathogenesis of ostial
stenoses may be affected by its proximity to the aorta and potential extension of atherosclerosis
from that vessel.
Anastomosis of IMA to the native coronary is the most frequent site of a target lesion. The
particular anatomical feature of the IMA-to-LAD anastomosis is subjected to continuous
mechanical stress, owing to the asynchronous motion of heart, lungs and bypass. Moreover,
it has been suggested that this predilection reflects scar tissue induced by injury during surgical
manipulation. [169]
Published reports have demonstrated that BA of the IMA can be performed safely with high
procedural success and a low incidence of clinical restenosis. [170-175] The use of BMS
compared to BA alone for percutaneous revascularization of the IMA graft was investigated
in several studies. In a large cohort of 174 patients who underwent BA or BMS placement,
anastomotic lesions were more evident, 63% of al cases. [169] These lesions were more
commonly treated with BA (91%), whereas lesions located at the ostium (8%) were more
frequently treated with stents (69%). Patients who underwent stenting had a target lesion
revascularization rate of 15.4% and those who underwent BA had a rate of 5.4%. In a retro‐
spective analysis patients undergoing BMS implantation for the treatment of IMA graft
stenosis were compared to patients treated with BA. [176] The minority of patients were treated
Treatment of Coronary Artery Bypass Graft Failure
http://dx.doi.org/10.5772/54928
207
with BMS (26.4%) and received at least either ticlopidine or clopidogrel for 4 weeks post PCI.
Angiographic success after stenting was high, 92%. At 1 year follow-up, target lesion revas‐
cularization rates were significantly higher in the stented lesions than lesions treated with BA
alone (19.2% vs. 4.9%) and the higher rate in stented lesions was most apparent at the anasto‐
motic site (25.0% vs. 4.2%). Moreover, a significant difference was observed between 1-year
all-cause mortality between stented lesions and lesions treated with BA alone (13.6% vs. 4.4%),
no difference was observed for MI. In a multivariate analysis including all available baseline
factors contributing to target lesion revascularization, indicated that stent use was an inde‐
pendent predictor. In this observational study selection bias may have resulted in more lesions
at high risk of restenosis being chosen for stenting, as stenting was at the discretion of the
operator.
Comparison of BMS and DES for percutaneous revascularization of IMA Grafts, have reported
conflicting results. In a retrospective study, outomes after BMS and DES treatment in IMA
grafts were evaluated. [177] Baseline characteristics were comparable between the 2 groups,
except for a trend toward longer stent lengths in the DES group (DES 20.2±7.7 mm vs. BMS
14.8±3.5 mm). No significant differences were present in in-hospital and 1- or 6-month
outcomes between the 2 groups, including target lesion revascularization with DES (DES 3.33%
vs. BMS 10%). Contrastingly, 2 small studies did not show improved clinical impact of DES
compared to BMS. At 1-year clinical follow-up, no differences were detected in target lesion
revascularization rates after treatment with BMS and PES (26.6% vs. 25%). [178] In the PES
group, 2 late stent thromboses were observed. In addition, in a small study the long-term
outcomes of 41 patients undergoing PCI of the IMA anastomosis BMS or SES were compared.
[179] At a median follow-up of 29.2 months (interquartile range, 11.1-77.7 months) target lesion
revascularization was 47.8% with SES and 7.1% with BMS. Patients who underwent repeat
revascularization were more likely to have longer stents than those who did not (18.2 mm vs
14.2 mm).
The favourable results of BA compared to stenting in IMA graft intervention is in contrast with
native coronary artery intervention. This might be explained by the fact that: 1) the proliferative
response to BA in IMA may be less aggressive than that in native coronary arteries; 2) in native
coronary arteries as compared to BA, stenting leads to more pronounced arterial injury, greater
inflammatory response, and enhanced neointimal formation; 3) in small native coronary
arteries, the high stent-to-wall ratio might predispose restenosis more frequently; and 4) stents
are known to be thrombogenic and lead to neointimal formation and restenosis. [180-183]
Percutaneous treatment of ostial stenosis, presents technical challenges for the intervention‐
alist whereas lesions in the shaft are most similar to routine intervention in a native coronary
arteries. Stenting of the anastomotic site takes carefully positioning of the stent to achieve
apposition to the arterial wall given the acute angle at which IMA meets the native coronary
artery. In one observational study a difference in 1-year target lesion revascularization rates
was present at the ostial, shaft, and anastomotic sites (30.8%, 5.0%, and 7.2%, respectively).
[176] The anastomosis experiences a bending of the stent with strut shrinkage and might cause
stent fracture or in DES might limit elution of drug to vessel wall.
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Failure of the RA graft is most frequently a complete occlusion and less often a string-like
appearance. However, on rare occasions, focal stenoses of the RA graft can occur.
RA graft stenosis treated by percutaneous intervention was evaluated in a small study
including 18 patients. [184] The location of the RA stenosis was proximal (n = 2), shaft (n = 11)
or distal anastomosis (n = 5). BA alone was performed on nine RA grafts at 1.7 years after
surgery and stenting (3 BMS, 6 DES) of nine RA grafts was achieved at 9.2 years after surgery.
At 5.8 years, clinical follow-up showed heart failure (n = 2) and recurrent angina (n = 3), all
after balloon dilatation. At 4.5 years, 1 RA graft was occluded due to competitive flow from
the native coronary vessel and 2 RA restenoses following BA were treated by stenting. Intra-
stent RA stenosis was noted in 1 patient. PCI with BA should be restricted to the early
postoperative period during which spasm is difficult to exclude. Stenting showed excellent
and durable results and is preferred in most cases. There are no large studies on other arterial
grafts to draw definite conclusions for the treatment with PCI by BA, BMS or DES.
Antithrombotic therapy during graft intervention - The preferred parenteral antithrombotic
therapy during graft intervention remains to be explored. The role of glycoprotein IIb/IIIa
antagonists in graft intervention is limited as they failed to demonstrate a reduction in
periprocedural MI. [185-187] Similarly, no reduction in MACE at 30 days was observed in a
post hoc analysis when glycoprotein IIb/IIIa antagonists were used in conjunction with filter-
based embolic protection, although there was a trend toward improved procedural success.
[188] In contrast, bivalirudin as compared with unfractionated heparin may have beneficial
effects on biochemical and clinical outcomes as it was associated with a significant reduction
in CK-MB elevation and a trend toward lower in-hospital non–Q-wave MI, repeat revascula‐
rization, and vascular complications. [189] Moreover, bivalirudin may offer a safety advantage
over heparin plus a glycoprotein IIb/IIIa anatagonist as minor bleeding complications were
lower with bivalirudin alone (26% vs. 38%) with equal or greater suppression of adverse
ischemic events. [190] Pharmacological treatment of slow or no-reflow is targeted at micro‐
vascular flow with intragraft administration of vasodilators and delivery of pharmaceutical
agents to the distal microvasculature and can be maximized with a microcatheter like an
aspiration thrombectomy catheter. Adenosine is an endogenous purine nucleoside, a vasodi‐
lator of arteries and arterioles, and inhibits platelet activation and aggregation. A high dose of
intragraft adenosine (≥5 boluses of 24 µg each) can result in reversal of slow or no-reflow and
improve final Thrombolysis In Myocardial Infarction (TIMI) flow grade. However, the use of
adenosine is limited because severe bradycardia may occur due to its effect on sinoatrial and
atrioventricular nodal conduction and the half-life of adenosine is very short. Intracoronary
administration of nitroprusside, a direct donor of NO, results in a rapid improvement in both
angiographic flow and blood flow velocity. Caution is warranted in patients who are volume
depleted or hypotensive at baseline because profound hypotension may occur. Prophylactic
intragraft administration of verapamil (100 to 500 µg) can reduce the occurrence of no-reflow
and improve TIMI myocardial perfusion grade. Prophylactic intragraft administration of
nicardipine, a potent arteriolar vasodilator, may reduce CK-MB elevation. Independent
predictors for slow flow or no-reflow are probable patients treated for ACS, stent thrombosis,
diseased SVG, and lesion ulceration.
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Embolic protection Devices - Graft intervention, in particular SVG, can be complicated by distal
embolization of atheroembolic debris leading to decreased epicardial and microvascular
perfusion due to capillary plugging and vasospasm from the release of neurohumoral factors.
Distal embolization may result in the slow or no-reflow and is associated with periprocedural
myocardial necrosis and increased in-hospital mortality. However, distal embolization
remains difficult to predict. Several embolic protection devices are available to prevent distal
embolization and in SVG intervention it is recommended a class I according to the ACC/AHA
guideline. [191] Distal balloon systems provide occlusion beyond the lesion securing the blood
and may prevent plaque embolization into the myocardial bed. Hereafter, the blood with
contained debris can be aspirated before occlusive balloon deflation. Advantages are the low
crossing profile and entrapment of debris of all sizes as well as neurohumoral mediators such
as serotonin and thromboxane that may have an adverse effect on the distal microvasculature.
However, disadvantages are: 1) the need to cross the lesion before adequate protection,
possibly liberating friable material before balloon occlusion; 2) temporary cessation of blood
flow leading to ischemia and possible hemodynamic instability, as well as limiting visualiza‐
tion making accurate stent placement difficult; 3) inability to obtain full evacuation, especially
near the occlusion balloon; 4) possible traumatic injury to the SVG during balloon occlusion,
and 5) the need for a relatively disease-free landing zone of approximately 3 cm distal to the
lesion for placement of the occlusion balloon. [192] The PercuSurge GuardWire (Medtronic,
Minneapolis, Minnesota) and the TriActiv embolic protection system (Kensey Nash Corpora‐
tion, Exton, Pennsylvania) both demonstrated a significant decrease the incidence of no-reflow
and improved 30-day clinical outcome but the latter was associated with more vascular
complications and the need for blood transfusion. [193,194]
Distal filter systems, composed of a tightly wrapped filter attached to a guidewire and sheathed
within a delivery catheter for placement distal to the target lesion, can trap debris that embolize
while the intervention is performed over the guidewire. After the intervention, a retrieval
catheter is advanced over the guidewire to collapse the filter and remove it along with retained
contents. It is ease-of-use and antegrade blood flow during intervention is maintained to avoid
ischemia allowing the ability to inject contrast media to facilitate accurate balloon inflation or
stent placement. Distal filter systems may be preferred in high-risk patients who are at
increased risk for hemodynamic instability such as patients with severe left ventricular
dysfunction or last remaining conduit. These systems do need a high crossing profile (large
diameter sheath approximately 3- to 4-F) and the maneuverability is poor. Moreover, the
inability to completely entrap microparticles, possible occlusion of the filter due to large
amounts of debris, and inability to use in very distal lesions because of the need for a landing
zone to deploy the filter are some other disadvanteges. The FilterWire EX (Boston Scientific)
and the FilterWire EX (Boston Scientific) both showed noninferiority to distal balloon occlusion
devices. [195]
The Proxis embolic protection system (St. Jude Medical, Maple Groves, Minnesota), a proximal
balloon occlusion device, employs a distal balloon to seals the SVG while a proximal balloon
seals the inside of the guiding catheter. This secures the blood with debris from embolizing
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downstream into the microvasculature. After the intervention, the blood with the debris can
be aspirated with a suction catheter before deflating the balloon. The advantages are that
protection from distal embolization of atheromatous debris can be established before crossing
the lesion, side branches can be protected, and distal lesions that are not amenable to distal
embolic protection because of lack of a landing zone can be treated. The device can not be used
in ostial or very proximal lesions as approximately 15 mm of landing zone is required, and the
device causes cessation of antegrade perfusion resulting in myocardial ischemia. The multi‐
center prospective randomized PROXIMAL trial determined outcomes of the Proxis embolic
protection device compared to distal protection devices during stenting of degenerated SVG.
[196] In a subset of 410 patients with lesions amenable to treatment with either proximal or
distal protection devices the primary composite end point, death, MI, or target vessel revas‐
cularization at 30 days, occurred in 12.2% of distal protection patients and 7.4% of proximal
protection patients.
The decision regarding whether or not to intervene in a diseased graft should be guided by
the patient’s symptoms, angiographic evidence of a significant stenosis, and noninvasive
evidence of myocardial ischemia in the region subtended by the bypass graft. Fractional flow
reserve (FFR) measurement to assess the significance of stenosis in a bypass graft can be
performed in a similar fashion as in a native coronary vessel and guide decision making.
Moreover, risk-scoring models are considered to be valuable in predicting outcomes and
guiding to appropriate treatment strategies for patients undergoing PCI. Although, the
SYNTAX score, developed to characterize angiographic complexity, has been proposed to
predict outcomes and select an optimal treatment strategy for patients with coronary artery
disease, the score is complex and does not take into account patients with coronary bypass
graft lesions. [197-199] The Duke myocardial jeopardy score was developed in the 1980s as a
simple method to estimate the amount of myocardium at risk for ischemia on the basis of the
location of a coronary lesion in non-surgically managed patients with coronary artery disease.
[200] Recently, an adjustment was suggested to this score to include left main disease as well
as the protective properties of patent bypass grafts, the modified Duke jeopardy score (Figure
1). [201] The same assumptions are used as in the original score, assigning greater prognostic
significance to more proximal lesions than more distal lesions in the same vessel. Noteworthy,
the modified Duke jeopardy score has not been validated yet.
Acute coronary syndrome - After CABG, progression of atherosclerosis occurs both in grafts and
native coronary arteries, resulting in significant morbidity and mortality, especially in patients
who present with acute ACS. Estimates from the Coronary Artery Surgery Study and Veteran’s
Affairs Cooperative Study of Coronary Bypass indicate a rate of MI of approximately 2% to
3% per year over the first 5 years after CABG, with recurrent infarction in as many as 36% of
patients at 10 years and even higher rates of hospitalization for recurrent ischemia. [202-204]
Although primary PCI is the preferred strategy for STEMI patients, current guidelines do not
provide specific recommendations on the optimal reperfusion strategy in patients with prior
CABG. [205] Compared to patient without prior CABG, patients with prior CABG presenting
with ACS are older, have more cardiovascular risk factors, more frequent comorbidities, higher
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TIMI risk score, lower left ventricular ejection fraction, had higher prevalence of previous
treatment with evidence-based medications, were less likely to have ST-segment deviation or
positive cardiac biomarker on presentation. [206-209] During hospitalization prior CABG
patients experienced larger infarct size, were less likely to receive reperfusion therapy, early
invasive therapy and were more likely to be managed medically when compared to non-CABG
patients. [207,209] However, the efficacy of reperfusion therapy in patients with previous
CABG is less well characterized. Given the large amount of atherosclerotic material and
thrombus burden with limited runoff found in occluded SVG, it is suggested that reperfusion
success rate is reduced. In the GUSTO-1 (Global Utilization of Streptokinase and TPA for
Occluded Arteries I) trial a significantly increase in 30-day mortality was observed following
reperfusion with tissue-type plasminogen activator in prior CABG patients compared to those
without prior CABG (10.7% vs. 6.7%). [210] In addition, the prior CABG group also suffered
more pulmonary edema, hypotension, or cardiogenic shock and a lower TIMI flow grade 3
rate was achieved (31% vs. 49.2%). In the PERSUIT (Platelet Glycoprotein IIb/IIIa in Unstable
Angina: Receptor Suppression Using Integrilin Therapy) trial the efficacy of eptifibatide, a
Glycoprotein IIb/IIIa antagonist, in patients with ACS was compared in patients with or
without prior CABG. [88] After adjusting for differences in baseline characteristics and
treatment, patients with prior CABG had a significantly higher mortality rates at 6 months. At
30 days, there was a similar effect on the primary end point of death or MI in the eptifibatide
group versus the placebo group in prior CABG patients and in patients without a history of
CABG. Finally, in the ACUITY (Acute Catheterization and Urgent Intervention Triage
Strategy) Trial patients with prior CABG presenting with ACS were randomized to bivalirudin
or heparin plus a glycoprotein IIb/IIIa inhibitor. [209] Bivalirudin monotherapy did not
Figure 1. Modified Duke Jeopardy Score
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improve short-term or long-term prognoses in ACS patients with prior CABG. Currently, the
optimal antithrombotic therapy for patients with prior CABG presenting with ACS is not
known, and existing data are conflicting.
As the non-invasive treatment did not significantly improve outcomes in patients with prior
CABG presenting with ACS a percutaneous strategy was investigated. Invasive versus non-
invasive treatment in ACS and prior CABG was evaluated in the GRACE (Global Registry of
Acute Coronary Events), and 6-month mortality was lower in patients revascularized versus
those treated medically by univariate but not by multivariable analysis. [211] Similarly, in a
large Swedish registry of 10,837 patients with previous CABG, 1-year adjusted mortality was
reduced with 50% with revascularization compared with medical management. [212]
Long-term clinical follow-up of ACS patients with prior CABG treated with PCI has been
assessed in several studies. In a small study, 34 consecutive patients with ACS who underwent
PCI with DES for occluded SVG, showed a procedural success rate of 81%. [213] At 3-year
follow-up mortality was 42%, recurrent ACS was 41% and repeat intervention was 38%. In a
recently published retrospective analysis, the outcomes after PCI with BMS or DES for ACS
due to graft failure were evaluated. [214] Although the majority of the 92 patients included
were treated with BMS (84%), the groups were comparable for baseline clinical and angio‐
graphic characteristics. Graft failure occurred mainly in the SVG (90%), but also arterial grafts
(LIMA and RIMA) were treated (8.7%). The initial restoration of normal blood flow was
approximately 80%. The primary endpoint of death, MI, target vessel revascularization at 5-
year follow-up was 65.9% in the BMS group and 43.4% in the DES group, this difference did
not reach statistical significance. Individual endpoints at 5 years were also comparable between
BMS and DES groups (death 46% vs. 43%, MI 36% vs. 33%, target lesion revascularization 26%
vs. 15%, respectively). Predictors for the composite endpoint were cardiac shock (HR= 6.13;
95%-CI:3.12-12.01), creatinin (HR=1.006; 95%-CI:1.001-1.011), and multi-vessel disease (HR=
4.64; 95%-CI:1.40-15.41). Cardiac shock and creatinin also predicted for death.
The beneficial effect of redo CABG over PCI was examined in the randomized AWESOME
(Angina With Extremely Serious Operative Mortality Evaluation) trial in which 3-year survival
and freedom from recurrent ACS was similar among patients with prior CABG and refractory
myocardial ischemia, although patients favoured PCI. [215]
Patients with an acute MI / STEMI from a SVG culprit undergoing PCI are a high-risk subset
of an already high-risk population. In the PAMI-2 (Second Primary Angioplasty in Myocardial
Infarction) trial demonstrated lower angiographic success rates and higher mortality rates after
BA in 58 patients with prior CABG compared with the 1068 patients without prior CABG.
Primary PCI in patients with acute MI and prior CABG showed that patients treated with BA
or BMS in SVG grafts compared to patients in whom a native vessel was treated had more no-
reflow at initial treatment (8.9% vs. 1.6%) and significantly more MI at 1 year follow-up (26%
vs. 11%). [130] In another study, outcomes of 192 patients with acute MI from a SVG culprit
undergoing PCI were compared to patients with a native culprit. [216] After multivariable
adjustment, SVG culprit remained significantly associated with lower levels of peak troponin.
The likelihood of MACE was higher in SVG vs. native culprits in patients with small to modest
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troponin elevations. Patients with a SVG culprit also suffered higher rates of mortality at 30
days (14.3% vs. 8.4%) and MACE at 1 year (36.8% vs. 24.5%). Finally, in the APEX-AMI trial,
STEMI patients with prior CABG exhibited a smaller baseline territory at risk as measured by
12-lead ECG and had less myocardial necrosis. Moreover, in these patients receiving primary
PCI, TIMI flow grade 3 was less frequently achieved and ST-segment resolution was less
common but they have more frequent clinical comorbidities and increased 90-day clinical
events including mortality. Risk factors for mortality were prior heart failure and age.
In conclusion, in patients with prior CABG presenting with ACS, PCI improves clinical
outcomes compared to medical therapy alone. Redo CABG does not seem to further improve
clinical outcomes.
11. Redo CABG for graft failure
Redo CABG is considered when revascularization of the LAD or a large area of the myocar‐
dium is required. Redo CABG is also preferred in patients with prior CABG with no patent
grafts present but left main disease or 3-vessel disease, and in those with disabling angina,
despite optimal non-surgical therapy, including lesions unsuitable for PCI. [217]
Surgeons are posed with a number of challenges in patients requiring redo CABG, including
a higher likelihood of technical complications, incomplete revascularization, inadequate
myocardial preservation, lack of suitable conduits, neurologic complications including major
disabling stroke, renal failure, peri-operative bleeding and ischemia. [218,219] To help decrease
the risks associated with redo CABG, a number of technical advances have been introduced
in the surgical arena. The first challenge, safe sternal re-entry without damaging coronary
bypass grafts and other retrosternal structures, has been described to be safely performed when
using an oscillating or micro-oscillating saw. [220,221] Periodic deflating of the lungs will help
prevent injury to the pulmonary parenchyme during re-entry. When a mammary artery was
used in the first surgery, there are generally four types of mammary artery to sternal relation‐
ships that can be encountered. [219] The first: LIMA and RIMA are both used with the LIMA
supplying the LAD and the RIMA reaching to the RCA or its branches. In this case, the risk of
injury is relatively low, because the IMA grafts are parallel to the body of the sternum at a
deeper plane and go through the pericardium (which is therefore open) directly away from
the midline toward the target vessels. In a second situation, a pedicle LIMA graft crosses in
front of the pleura, curves around and goes back laterally to reach the LAD, which is typically
seen as a C-shaped curve on the angiogram. This type of LIMA grafting is particularly prone
to injury during sternotomy because of its close proximity to the sternal body. In the third
scenario, the RIMA graft is used and comes in front of the aorta across the midline and reaches
the LAD. Although the graft crosses the midline the risk of injury is relatively low due to the
close proximity to the aorta which lies deeper in the thorax and can be easily identified. Finally,
the RIMA may go behind the aorta through the transverse sinus to reach the marginal branches
of the Cx artery, which is very far away from the sternal re-entry area and poses therefore
minimal risk for potential injury. The proximity of vein grafts to the sternum varies signifi‐
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cantly due to the large number of options for proximal as well as distal anastomosis sites.
Careful review of the coronary angiogram or even cardiac/thoracic imaging to assess the
relationship to the sternum and other anatomic structures is therefore warranted. Other
structures at risk for injury during sternal re-entry include perforation of the right ventricle,
and innominate vein. This is particularly true in patients where the pericardium was not
closed. After sternal access, subsequent exposure of the heart can be completed by fibrosis
which can be significant especially after pericarditis or radiation exposure. In patients
requiring posterior vessel bypass, the entire heart should be cleared of fibrosis to allow surgical
manipulation.
After sternal entry and inspection of the coronary vessels and branches, the second challenge
is to assure adequate revascularization. Diffuse coronary artery disease poses a major problem
in finding a suitable and satisfactory area for anastomosis. Thick plaque build-up and calcified
coronary artery branches as well as calcification of the aortic arch make distal and proximal
anastomosis of coronary bypass grafts hard and increase the chances of graft failure. [219]
Additionally, the lack of satisfactory bypass conduits is common, because many patients
undergoing redo CABG have very thin and dilated varicose veins, and small and calcified
radial arteries. Risk factors for poor saphenous vein quality are age, obesity and diabetes,
which are all more prominent in patients requiring redo CABG. In those patients the IMA may
be small or even atherosclerotic.
Inadequate myocardial protection is an important cause of failure to wean patients off
cardiopulmonary bypass. In the presence of degenerative old vein grafts, delivery of cardio‐
plegia solution is considered safer through retrograde coronary sinus perfusion than anterog‐
rade delivery of cardioplegic solution because of the risk of atheromatous embolization from
atherosclerotic vein grafts which can lead to acute occlusion of coronary artery branches. [222]
Additional measures include a no touch approach regarding diseased vein grafts to minimalize
the chance of distal embolization due to manipulation. [223] To assure a constant temperature
in an attempt to minimize haematological abnormalities and tissue edema, some surgeons also
occlude the IMA with a bulldog clamp to prevent the delivery of warm blood into the
myocardium. In such a way, the entire myocardium is provided with continuous, cold
cardioplegic solution through coronary sinus perfusion. [224,225] After placement of newly
constructed coronary artery bypass grafts, anterograde cardioplegic solution can also be given.
Neurological complications and bleedings are common following redo CABG. Several
techniques are used to decrease the risk of neurological complications. Most common are
ischemic stroke or TIA due to cerebral embolization from a calcified ascending aorta, athe‐
romatous plaques on the ascending aorta, and embolization from a jet phenomenon from aortic
cannulation. Other causes for cerebal dysfunction are systemic inflammatory processes in
response to cardiopulmonary bypass and gaseous microemboli. [226] Soft flow aortic cannu‐
lae, heparin-coated circuits, and administration of adenosine have proposed as techniques to
lower neurological complications, but adequate studies and therefore evidence are lacking.
[227-229] Bleeding is associated with an increased morbidity and mortality. Bleedings can be
largely avoided by meticulous surgical dissection and careful catherization. Some studies
using the application of fibrin glue suggest that this may help minimize peri-operative
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bleeding. [230] Intraoperative blood loss is a major cause of post-operative bleeding from
depleted coagulation factors and hemodilution. Consideration should be given to preoperative
antiplatelet therapy including aspirin and clopidogrel. A low platelet count and other medical
conditions that adversely affect the coagulation process should be carefully investigated.
Redo CABG for coronary bypass graft failure is not favoured by cardiologists and surgeons
alike, due to the higher morbidity and mortality compared with primary CABG. Reported
intraoperative mortality rates are 5.8-9.6%. [231] Other major complications include stroke
(1.4-3.2%), non-fatal MI (3.0-9.6%), renal failure (2.4-11%) and post-operative bleeding
(2.7-4.4%). [217,223] Following redo CABG, survival is 75–90% and 55–75% at 5- and 10-year
follow-up, respectively. [231]
Redo CABG versus PCI - Available data comparing the outcomes of PCI to redo CABG in
patients with prior CABG is limited. Initial studies evaluating BA versus CABG noted
comparable long-term results except for a much higher rate of repeat revascularization in the
BA group (BA 64% vs. redo CABG 8%). [232] Multivariate analysis identified age > 70 years,
left ventricular ejection fraction < 40%, unstable angina, number of diseased vessels and
diabetes mellitus as independent correlates of mortality for the entire group. Direct compari‐
son between redo CABG and PCI was performed in the AWESOME trial. A total of 142 patients
with refractory post-CABG ischemia and at least one of five high-risk features (i.e. prior open-
heart surgery, age >70 years, left ventricular ejection fraction <35%, MI within seven days or
intraaortic balloon pump required) amandable for either PCI or redo CABG were randomized.
[17] Arterial grafts were used in 75% of redo CABG procedures and stents in 54% of PCI
(approximately one-half with BMS). In-hospital mortality was higher after redo CABG (8% vs.
0%). At 3 years, there was no significant difference in overall patient survival (redo CABG 71%
vs. PCI 77%), but there was a nonsignificant increase in survival free of unstable angina in the
CABG group (65% vs. 48%). In the much larger retrospective observational study from the
Cleveland Clinic of 2191 patients with prior CABG who underwent multivessel revasculari‐
zation between 1995 and 2000 were evaluated. [233] A total of 1487 had redo CABG and 704
underwent PCI (77% with at least one stent). No difference was observed in 30-day mortality
with redo CABG compared to PCI (2.8% vs. 1.7%) but as expected periprocedural Q wave MI
occurred more often after redo CABG (1.4% vs. 0.3%). At 5-years follow-up, cumulative
survival was similar with redo CABG and PCI (79.5% vs. 75.3%). After adjustment, PCI was
associated with a nonsignificant increase in mortality risk (hazard ratio 1.47, 95% CI 0.94-2.28).
The major predictors of mortality were higher age and lower LVEF, not the method of
revascularization. Importantly, the choice of treatment strategy was largely determined by
coronary anatomy wherein the most important factors to perform redo CABG were: 1) more
diseased or occluded grafts, 2) absence of a prior MI, 3) lower left ventricular ejection fraction,
4) longer interval from first CABG (15 vs. 6 years), 5) more total occlusions in native coronary
arteries, and 6) the absence of a patent mammary artery graft.
In diabetic patients with post-CABG angina, the outcomes after repeat revascularization were
evaluated in an observational study in which 1123 such patients underwent PCI (75% BA, 25%
stent palcement) and 598 underwent redo CABG. [234] Redo CABG was associated with
increased in-hospital mortality (11.2% vs. 1.6%) and stroke (4.7% vs. 0.1%). At 10 years, there
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was no significant difference in mortality between groups (redo CABG 74% vs. PCI 68%).
Noteworthy, the available comparative studies were, however, conducted before the use of
aggressive dual antiplatelet therapy with aspirin and clopidogrel after PCI with stenting and
aggressive lipid-lowering with statins for secondary prevention.
In a recently published retrospective study, in which patients were prescribed aggressive
dual antiplatelet therapy, 287 consecutive patients with graft failure were assigned by the
heart-team to PCI or redo CABG. [235] A total of 243 patients underwent PCI (82% treat‐
ed with BMS, 18% treated with DES) and 44 redo CABG. Patient selection was present as
patients  undergoing  PCI  more  frequently  presented  with  STEMI,  multivessel  disease,
SVG failure, a history of MI, and shorter time-to-graft failure. At 5 year, the rate of com‐
posite all-cause death, MI or target vessel revascularization was comparable,  57.6% after
PCI and 51% after redo CABG. Target lesion revascularization was 21.3% after PCI, and
3.2%  following  redo  CABG.  In  the  PCI  group,  BMS  was  associated  with  significantly
higher  rates  of  target  lesion revascularization (24.8% vs.  7.6%),  but  the  rate  of  death or
MI compared with DES was similar.  Independent predictors for  the composite  outcome
were creatinine and peak creatine kinase MB. These results have to be confirmed in larg‐
er studies before definite conclusion can be drawn.
12. Conclusion
Patients with prior CABG remain at risk for future cardiac events, including graft failure. Stable
patients with recurrence of angina following CABG can be treated medically for their symp‐
toms and risk factor reduction. In all patients with coronary heart disease aggressive risk factor
reduction is recommended which includes aspirin, treatment for hypertension and serum
lipids, avoidance of smoking, and controlling serum glucose in diabetic patients. Evaluation
for ischemia is as in other patients with stable angina without prior CABG. However, early
diagnostic angiography is suggested as the different anatomic possibilities, i.e. graft stenosis
or progression of native vessel disease in nonbypassed vessels can lead to recurrent ischemia.
Revascularization of graft failure either by PCI or redo CABG is associated with worse acute
and long-term outcomes compared to patients without prior CABG. The choice of treatment
modality is influenced by clinical and angiographic characteristics. When multiple grafts are
occluded or the graft or native coronary artery appears unsuitable for PCI, surgery should be
favoured. The target for PCI is the body of the coronary artery of the arterial graft while freshly
occluded SVG or the anastomosis itself should be targeted due to the risk of embolization or
perforation. Whether specific stent platforms, polymers or drugs are more appropriate in SVG
and arterial graft lesions has not been addressed at this time. Moreover, the role of various
surgical techniques for graft revascularization, such as off-pump and minimal invasive CABG
also remain unclear. Finally, factors including disease status of the native vessel, and patient
characteristics such as left ventricular function, renal failure, diabetes and advanced age, as
shown in our multivariate analysis are of influence on outcomes. Future prospective studies
in the medical and invasive treatment of graft failure are therefore warranted. Those studies
together with our growing understanding of the pathobiology of arterial and vein grafts will
Treatment of Coronary Artery Bypass Graft Failure
http://dx.doi.org/10.5772/54928
217
ultimately result in practical patient-tailored therapeutic strategies to enhance graft functionand control intimal hyperplasia and accelerated atherosclerosis.
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